Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

Mara ten Kate, Frederik Barkhof, Marina Boccardi, Pieter Jelle Visser, Clifford R Jr. Jack, Karl Olof Lovblad, Giovanni B. Frisoni, Philip Scheltens

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Research criteria for Alzheimer's disease recommend the use of biomarkers for diagnosis, but whether biomarkers improve the diagnosis in clinical routine has not been systematically assessed. The aim is to evaluate the evidence for use of medial temporal lobe atrophy (MTA) as a biomarker for Alzheimer's disease at the mild cognitive impairment stage in routine clinical practice, with an adapted version of the 5-phase oncology framework for biomarker development. A literature review on visual assessment of MTA and hippocampal volumetry was conducted with other biomarkers addressed in parallel reviews. Ample evidence is available for phase 1 (rationale for use) and phase 2 (discriminative ability between diseased and control subjects). Phase 3 (early detection ability) is partly achieved: most evidence is derived from research cohorts or clinical populations with short follow-up, but validation in clinical mild cognitive impairment cohorts is required. In phase 4, only the practical feasibility has been addressed for visual rating of MTA. The rest of phase 4 and phase 5 have not yet been addressed.

Original languageEnglish (US)
Pages (from-to)167-182
Number of pages16
JournalNeurobiology of Aging
Volume52
DOIs
StatePublished - Apr 1 2017

Fingerprint

Atrophy
Alzheimer Disease
Biomarkers
Temporal Lobe
Aptitude
Research
Population
Cognitive Dysfunction

Keywords

  • Alzheimer's disease
  • Dementia
  • Hippocampus
  • Medial temporal lobe atrophy
  • Mild cognitive impairment
  • MRI
  • Roadmap

ASJC Scopus subject areas

  • Neuroscience(all)
  • Aging
  • Developmental Biology
  • Geriatrics and Gerontology
  • Clinical Neurology

Cite this

Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. / ten Kate, Mara; Barkhof, Frederik; Boccardi, Marina; Visser, Pieter Jelle; Jack, Clifford R Jr.; Lovblad, Karl Olof; Frisoni, Giovanni B.; Scheltens, Philip.

In: Neurobiology of Aging, Vol. 52, 01.04.2017, p. 167-182.

Research output: Contribution to journalReview article

ten Kate, Mara ; Barkhof, Frederik ; Boccardi, Marina ; Visser, Pieter Jelle ; Jack, Clifford R Jr. ; Lovblad, Karl Olof ; Frisoni, Giovanni B. ; Scheltens, Philip. / Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. In: Neurobiology of Aging. 2017 ; Vol. 52. pp. 167-182.
@article{8cfaa2905aac4b92ab022445dda1855e,
title = "Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework",
abstract = "Research criteria for Alzheimer's disease recommend the use of biomarkers for diagnosis, but whether biomarkers improve the diagnosis in clinical routine has not been systematically assessed. The aim is to evaluate the evidence for use of medial temporal lobe atrophy (MTA) as a biomarker for Alzheimer's disease at the mild cognitive impairment stage in routine clinical practice, with an adapted version of the 5-phase oncology framework for biomarker development. A literature review on visual assessment of MTA and hippocampal volumetry was conducted with other biomarkers addressed in parallel reviews. Ample evidence is available for phase 1 (rationale for use) and phase 2 (discriminative ability between diseased and control subjects). Phase 3 (early detection ability) is partly achieved: most evidence is derived from research cohorts or clinical populations with short follow-up, but validation in clinical mild cognitive impairment cohorts is required. In phase 4, only the practical feasibility has been addressed for visual rating of MTA. The rest of phase 4 and phase 5 have not yet been addressed.",
keywords = "Alzheimer's disease, Dementia, Hippocampus, Medial temporal lobe atrophy, Mild cognitive impairment, MRI, Roadmap",
author = "{ten Kate}, Mara and Frederik Barkhof and Marina Boccardi and Visser, {Pieter Jelle} and Jack, {Clifford R Jr.} and Lovblad, {Karl Olof} and Frisoni, {Giovanni B.} and Philip Scheltens",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.neurobiolaging.2016.05.024",
language = "English (US)",
volume = "52",
pages = "167--182",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

AU - ten Kate, Mara

AU - Barkhof, Frederik

AU - Boccardi, Marina

AU - Visser, Pieter Jelle

AU - Jack, Clifford R Jr.

AU - Lovblad, Karl Olof

AU - Frisoni, Giovanni B.

AU - Scheltens, Philip

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Research criteria for Alzheimer's disease recommend the use of biomarkers for diagnosis, but whether biomarkers improve the diagnosis in clinical routine has not been systematically assessed. The aim is to evaluate the evidence for use of medial temporal lobe atrophy (MTA) as a biomarker for Alzheimer's disease at the mild cognitive impairment stage in routine clinical practice, with an adapted version of the 5-phase oncology framework for biomarker development. A literature review on visual assessment of MTA and hippocampal volumetry was conducted with other biomarkers addressed in parallel reviews. Ample evidence is available for phase 1 (rationale for use) and phase 2 (discriminative ability between diseased and control subjects). Phase 3 (early detection ability) is partly achieved: most evidence is derived from research cohorts or clinical populations with short follow-up, but validation in clinical mild cognitive impairment cohorts is required. In phase 4, only the practical feasibility has been addressed for visual rating of MTA. The rest of phase 4 and phase 5 have not yet been addressed.

AB - Research criteria for Alzheimer's disease recommend the use of biomarkers for diagnosis, but whether biomarkers improve the diagnosis in clinical routine has not been systematically assessed. The aim is to evaluate the evidence for use of medial temporal lobe atrophy (MTA) as a biomarker for Alzheimer's disease at the mild cognitive impairment stage in routine clinical practice, with an adapted version of the 5-phase oncology framework for biomarker development. A literature review on visual assessment of MTA and hippocampal volumetry was conducted with other biomarkers addressed in parallel reviews. Ample evidence is available for phase 1 (rationale for use) and phase 2 (discriminative ability between diseased and control subjects). Phase 3 (early detection ability) is partly achieved: most evidence is derived from research cohorts or clinical populations with short follow-up, but validation in clinical mild cognitive impairment cohorts is required. In phase 4, only the practical feasibility has been addressed for visual rating of MTA. The rest of phase 4 and phase 5 have not yet been addressed.

KW - Alzheimer's disease

KW - Dementia

KW - Hippocampus

KW - Medial temporal lobe atrophy

KW - Mild cognitive impairment

KW - MRI

KW - Roadmap

UR - http://www.scopus.com/inward/record.url?scp=85015391763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015391763&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2016.05.024

DO - 10.1016/j.neurobiolaging.2016.05.024

M3 - Review article

VL - 52

SP - 167

EP - 182

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

ER -